Acorda Therapeutics Inc

NASDAQ ACORQ

Download Data

Acorda Therapeutics Inc Inventory Turnover Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Acorda Therapeutics Inc Inventory Turnover Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The inventory turnover ratio measures the efficiency of a company's inventory management by assessing how quickly it sells and replaces its inventory. It is calculated by dividing the cost of revenue by the average inventory value. This ratio indicates the number of times the company's inventory is sold and replaced within a specific period. A higher turnover ratio suggests efficient inventory management, while a lower ratio may indicate slow sales or excess inventory. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: ACORQ

Acorda Therapeutics Inc

CEO -
IPO Date Feb. 10, 2006
Location United States
Headquarters 2 Blue Hill Plaza, Pearl River, NY, United States, 10965
Employees 102
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

StockViz Staff

September 19, 2024

Any question? Send us an email